Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

New InsiGHTS: A Multicenter, Phase 2, Randomized, Open-label, Active-controlled, Parallel Group Clinical Trial to Investigate the Safety, Tolerability, and Efficacy of Different Dose Levels of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Individuals With Turner Syndrome

NCT05690386 is registered in ClinicalTrials.gov with Ascendis Pharma Endocrinology Division A/S as lead sponsor.

NCT NCT05690386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05690386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
New InsiGHTS: A Multicenter, Phase 2, Randomized, Open-label, Active-controlled, Parallel Group Clinical Trial to Investigate the Safety, Tolerability, and Efficacy of Different Dose Levels of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Individuals With Turner Syndrome
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 15, 2023
Completion date
December 31, 2027
Enrollment
48 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

turner syndrome